CLINICAL_TRIALS
trial_result
· 2015-04-20
Clinical Trial Update: Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema [Phase 3]
Summary
Phase 3 study of intravitreal aflibercept for diabetic macular edema completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Regeneron Pharmaceuticals | Conditions: Diabetic Macular Edema | Phase 3 | Status: COMPLETED | Results posted: 2015-04-20